Advertisement

Related Videos

Welcome and Introduction to Vi3C

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Dec
22
Today In Oncology
Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma
Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders
MRI First Strategy May Be Safe for Prostate Cancer Detection
Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma
Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Conexiant Oncology Logo